The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

JANUARY 26, 2024

Key breakthroughs at the forefront include novel approaches to cancer treatment and diagnosis, the integration of artificial intelligence (AI) in oncology and the development of advanced preventive measures and care. Overcoming drug resistance: A major challenge in cancer treatment is the development of resistance to chemotherapy drugs.

Research 118

Research Gene Editing Gene Genetics 118

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

pharmaphorum

APRIL 7, 2021

billion-plus alliance with UK biotech Artios Pharma to develop precision medicines for cancer. The new deal with Artios allows Novartis to tap into Artios’ DDR technology platform, which focuses on compounds that can prevent cancer cells from repairing damage to their DNA via a process called synthetic lethality.

DNA 52

DNA Licensing Licensing Gene Therapy 52

The Pharma Data

JUNE 28, 2021

Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks. Financial terms of the agreement were not disclosed.

Licensing 52

Licensing Licensing Medicine Development 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

APRIL 20, 2022

Food and Drug Administration is warning the public of the risk of false results, inappropriate use and inappropriate interpretation of results with non-invasive prenatal screening (NIPS) tests, also called cell-free DNA tests or non-invasive prenatal tests (NIPT). director of the FDA’s Center for Devices and Radiological Health.

Genetics 52

Genetics Cosmetics Radiology Production 52